PMID- 32766169
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 10
DP  - 2020
TI  - Interactions Between Gut Microbiota, Host, and Herbal Medicines: A Review of New 
      Insights Into the Pathogenesis and Treatment of Type 2 Diabetes.
PG  - 360
LID - 10.3389/fcimb.2020.00360 [doi]
LID - 360
AB  - Herbal medicines (HMs) are a major subset of complementary and alternative 
      medicine. They have been employed for the efficient clinical management of type 2 
      diabetes mellitus (T2DM) for centuries. However, the related underlying 
      mechanisms still remain to be elucidated. It has been found out that microbiota 
      is implicated in the pathogenesis and treatment of T2DM. An interplay between gut 
      microbiota and host occurs mainly at the gastrointestinal mucosal barrier. The 
      host movements influence the composition and abundance of gut microbiota, whereas 
      gut microbiota in turn modulate the metabolic and immunological activities of the 
      host. Intestinal dysbiosis, endotoxin-induced metabolic inflammation, immune 
      response disorder, bacterial components and metabolites, and decreased production 
      of short-chain fatty acids are considered significant pathogenic mechanisms 
      underlying T2DM. The interaction between gut microbiota and HMs during T2DM 
      treatment has been investigated in human, animal, and in vitro studies. HMs 
      regulate the composition of beneficial and harmful bacteria and decrease the 
      inflammation caused by gut microbiota. Furthermore, the metabolism of gut 
      microbiota modulates HM biotransformation. In this review, we have summarized 
      such research findings, with the aim to improve our understanding of the 
      pathogenesis and potential therapeutic mechanisms of HMs in T2DM and to provide 
      new insights into specific targeted HM-based therapies and drug discovery.
CI  - Copyright (c) 2020 Zheng, Gou, Zhang, Gao, Wei, Yu, Pang, Tian, Tong and Li.
FAU - Zheng, Yujiao
AU  - Zheng Y
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Gou, Xiaowen
AU  - Gou X
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhang, Lili
AU  - Zhang L
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Gao, Hanjia
AU  - Gao H
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Wei, Yu
AU  - Wei Y
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Yu, Xiaotong
AU  - Yu X
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Pang, Bing
AU  - Pang B
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Tian, Jiaxing
AU  - Tian J
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Tong, Xiaolin
AU  - Tong X
AD  - Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Li, Min
AU  - Li M
AD  - Molecular Biology Laboratory, Guang'anmen Hospital, Chinese Academy of 
      Traditional Chinese Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200717
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 0 (Fatty Acids, Volatile)
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Dysbiosis
MH  - Fatty Acids, Volatile
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - *Microbiota
PMC - PMC7379170
OTO - NOTNLM
OT  - bacterial metabolites
OT  - gut microbiota
OT  - herbal medicines
OT  - therapeutic mechanisms
OT  - type 2 diabetes mellitus
EDAT- 2020/08/09 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/01/01
CRDT- 2020/08/09 06:00
PHST- 2020/02/11 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fcimb.2020.00360 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2020 Jul 17;10:360. doi: 10.3389/fcimb.2020.00360. 
      eCollection 2020.